Navigation Links
Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
Date:11/9/2007

NEW YORK, Nov. 9 /Xinhua-PRNewswire-FirstCall/ -- Discas, Inc. (Pink Sheets: DSCS.PK), ("the Company") announced today that on November 6, 2007, it entered into a stock purchase agreement with SNX Organic Fertilizers, Inc., ("SNXOF"), a Delaware corporation. SNXOF's sole asset is Beijing Shen Nong Xing Technology Co. Ltd. ("BSNX"), a high-tech company headquartered in Beijing. The Company specializes in the research and development of green and organic agricultural products, including organic bio fertilizers, green agricultural products, and various organic health products.

As a result, SNXOF acquired 50.001% of the capital stock of the Company. Dr. Huakang Zhou, President and CEO of SNXOF was also nominated as the sole officer and director of the Company.

About Beijing Shen Nong Xing Technology Co. Ltd (SNX)

The Company, headquartered in Beijing with two manufacturing facilities -- Daqing Shen Nong Xing Xiangyu Technology Co. Ltd. located in Daqing City and Heilongjiang Shen Nong Xing Hongyu Fertilizer Co. Ltd. located in Huanan County, Heilongjiang province -- was registered under the laws of the Peoples' Republic of China. The Company specializes in the research and development, manufacture and sale of green and organic agricultural products, including organic bio fertilizers, green agricultural products, and various organic health products.

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


'/>"/>
SOURCE Discas, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. Neuralstem Shares Accepted for Trading on Amex(R)
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):